Merger strengthens ophthalmic portfolio and accelerates
commercialization
COLUMBUS, Ohio, Aug. 19,
2024 /PRNewswire/ -- Visiox Pharmaceuticals, Inc.
announced today that it has entered into a definitive merger
agreement with Ocuvex Therapeutics, Inc. a privately held
ophthalmic pharmaceutical company focused on developing and
commercializing novel therapies for glaucoma and other disorders.
Ocuvex boasts a robust pipeline of near-term ophthalmic medicines.
The strategic combination is set to position the newly combined
entity as an emerging leader in the eye care sector with an
exciting portfolio of ophthalmic medicines.
Visiox's innovative products, including OMLONTI®
(omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine)
0.35%, and SDN-037 (difluprednate) 0.04%, will grow Ocuvex's market
presence and accelerate the commercialization of these promising
therapeutics. Going forward, the company will operate under the
Ocuvex name, building on Visiox's commitment to disrupting the
ophthalmic market through high-level collaboration with eye care
professionals.
"The combination of Visiox and Ocuvex makes for a perfect
match," said Ryan S. Bleeks, Chief
Executive Officer of Visiox. "We have reached significant
milestones with our products and Ocuvex is in a great position to
take these advancements forward and bring them to market faster and
emerge as a future leader in eye care."
About Visiox Pharmaceuticals, Inc.
Visiox is a privately funded biopharmaceutical company focused
on the development and commercialization of ophthalmic therapeutic
candidates to address highly prevalent diseases in need of new
treatment options. Each day is an opportunity for Visiox to disrupt
and revolutionize the current market to maximize patient and
physician satisfaction.
OMLONTI® (omidenepag isopropyl ophthalmic
solution) 0.002% is a relatively selective prostaglandin E2 (EP2)
receptor agonist, indicated for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension.
PDP-716 (brimonidine) 0.35% is a once daily brimonidine with
TearAct™ technology for glaucoma expected to launch
in early 2025. TearAct™ is a patented technology
that involves the use of resin microparticles in a complex
suspension form to improve the dosing frequency from TID to QD,
prolonging the release of drug by reducing the immediate exposure
and providing a slow, consistent, and sustained exposure. Glaucoma
is the second leading cause of blindness in the world, including
over 3 million Americans. Half of these patients are unaware they
have glaucoma.1
SDN-037 (difluprednate) 0.04% is a twice daily topical
difluprednate corticosteroid utilizing TJM™ (Tight
Junction Modulation) micellar platform that involves micelles to
modulate the tight junctions (TJs) providing powerful post-surgical
control of inflammation in a clear solution enabling convenient
dosing with a proven active ingredient. SDN-037 is expected to
launch mid-2025. Cataract extraction is the most frequently
performed eye surgery in the U.S., accounting for 70% of all ocular
surgeries. Over 50 million Americans are projected to have
cataracts by 2050.2
PDP-716, SDN-037, TearActä, and TJM™ delivery
technology were licensed by Visiox from Sun Pharma Advanced
Research Company Ltd. For more information, please visit Visiox
Pharma or LinkedIn.
- The Eye Diseases Prevalence Research Group,
Arch Ophthalmol. 2004; Prevent Blindness America
- Ocular Surgery Procedures: Market Scope, 2019
Corporate Contact
Ryan S. Bleeks
Chief Executive Officer
381973@email4pr.com
914-987-2876
View original content to download
multimedia:https://www.prnewswire.com/news-releases/visiox-pharmaceuticals-inc-announces-transformative-merger-with-ocuvex-therpeutics-inc-302224689.html
SOURCE Visiox Pharmaceuticals, Inc.